Moxetumomab Pasudotox-tdfk

 (MOK-see-TOO-moh-mab pah-SOO-doh-tox)

This page contains brief information about moxetumomab pasudotox-tdfk and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Lumoxiti
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Moxetumomab pasudotox-tdfk is approved to treat:

More About Moxetumomab Pasudotox-tdfk

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Moxetumomab Pasudotox-tdfk - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Moxetumomab Approved by FDA for Hairy Cell Leukemia

Targeted Cancer Therapies

Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia

Drug May Help Prevent Resistance to Toxin-Based Leukemia Therapy

Clinical Trials Accepting Patients

Find Clinical Trials for Moxetumomab Pasudotox-tdfk - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted: October 24, 2018
  • Updated: April 5, 2019